Deuterium depleted water as an adjuvant in treatment of cancer
Syroeshkin A., Levitskaya O., Uspenskaya E., Pleteneva T., Makarova M., Romaykina D., Ermakova D.
Systematic Reviews in Pharmacy
Vol.10, Issue1, P. S26-S31
Опубликовано: 2019
Тип ресурса: Обзор
DOI:10.5530/srp.2019.1s.19
Аннотация:
For more than 20 years, since 1993, the Hungarian National Institute of Pharmacy and Nutrition has been conducting a research on the mechanisms of antitumor activity of light water (deuterium depleted water - DDW). Long-term randomized clinical trials in numerous treatment centers in Hungary in compliance with the Good Clinical Practice (GCP) indicate a high sensitivity of tumor cells to lower levels of deuterium (D) in the body. The replacement of the ordinary water (D)/H = 140 ppm) by the “light” one (D/H = 20-105 ppm) is accompanied by a decrease in the size of the tumor, gradual necrosis of tumor cells, an increase in the median survival of cancer patients (prostate cancer, breast cancer, lung cancer, etc.). The content of deuterium in the body at the level of 10-12 mmol is an order of magnitude higher compared to essential trace elements, which makes it possible to predict its key role in biochemical processes. Indeed, mass-spectrometric analysis shows that deuterium bioaccumulati
Ключевые слова:
DDW; Deuterium depleted water; Tumor cells
antineoplastic agent; deuterium; deuterium depleted water; drinking water; trace element; unclassified drug; water; antineoplastic activity; bioaccumulation; blood sampling; breast cancer; cancer adjuvant therapy; clinical research; clinical trial (topic); drug mechanism; experimental animal; lung cancer; malignant neoplasm; mass spectrometry; muscle tissue; nonhuman; priority journal; prostate cancer; Review; treatment indication; tumor cell; tumor volume
Язык текста: Английский
ISSN: 0976-2779
Syroeshkin A.
Levitskaya O.
Uspenskaya E.
Pleteneva T.
Makarova M.
Romaykina D.
Ermakova D.
Сyроешкин А.
Левицкайа О.
Успенскайа Е.
Плетенева Т.
Макарова М.
Ромайкина Д.
Ермакова Д.
Deuterium depleted water as an adjuvant in treatment of cancer
Текст визуальный непосредственный
Systematic Reviews in Pharmacy
Vol.10, Issue1 P. S26-S31
2019
Обзор
DDW Deuterium depleted water Tumor cells
antineoplastic agent deuterium deuterium depleted water drinking water trace element unclassified drug water antineoplastic activity bioaccumulation blood sampling breast cancer cancer adjuvant therapy clinical research clinical trial (topic) drug mechanism experimental animal lung cancer malignant neoplasm mass spectrometry muscle tissue nonhuman priority journal prostate cancer Review treatment indication tumor cell tumor volume
For more than 20 years, since 1993, the Hungarian National Institute of Pharmacy and Nutrition has been conducting a research on the mechanisms of antitumor activity of light water (deuterium depleted water - DDW). Long-term randomized clinical trials in numerous treatment centers in Hungary in compliance with the Good Clinical Practice (GCP) indicate a high sensitivity of tumor cells to lower levels of deuterium (D) in the body. The replacement of the ordinary water (D)/H = 140 ppm) by the “light” one (D/H = 20-105 ppm) is accompanied by a decrease in the size of the tumor, gradual necrosis of tumor cells, an increase in the median survival of cancer patients (prostate cancer, breast cancer, lung cancer, etc.). The content of deuterium in the body at the level of 10-12 mmol is an order of magnitude higher compared to essential trace elements, which makes it possible to predict its key role in biochemical processes. Indeed, mass-spectrometric analysis shows that deuterium bioaccumulati